ICD-10 Code M06.00: Rheumatoid Arthritis Without Rheumatoid Factor – Complete Coding & Billing Guide

What Does ICD-10 Code M06.00 Mean?

ICD-10 code M06.00 designates rheumatoid arthritis without rheumatoid factor, unspecified site — a billable, valid diagnosis code for fiscal year 2026 (effective October 1, 2025 through September 30, 2026) under ICD-10-CM Official Coding Guidelines, Chapter 13: Diseases of the Musculoskeletal System and Connective Tissue. This code belongs to category M06.0 (seronegative rheumatoid arthritis) and is used when a clinician has confirmed a diagnosis of rheumatoid arthritis (RA) but lab results show negative or absent rheumatoid factor (RF), and the documentation does not specify the anatomical site affected.

Key attributes of M06.00 at a glance:

• Billable/specific: Yes — valid for HIPAA-covered transactions
• Applicable settings: Outpatient, inpatient, office visits, rheumatology clinics
• Serological status required: Documented negative or absent RF result
• Site specificity: Unspecified — use only when joint site is not documented
• MS-DRG assignment: Grouped under MDC 08, Diseases & Disorders of the Musculoskeletal System and Connective Tissue
• ICD-9-CM crosswalk: Approximate mapping only — no exact ICD-9 equivalent

What Conditions and Clinical Presentations Does M06.00 Cover?

M06.00 captures confirmed rheumatoid arthritis in patients who are seronegative — meaning their lab panel does not detect circulating rheumatoid factor, yet the clinical picture is consistent with RA. This is sometimes referred to in clinical notes as seronegative RA or, less commonly, as RF-negative inflammatory arthritis when the rheumatologist has ruled out competing diagnoses.

Clinical presentations appropriately captured by M06.00 include:

• Symmetric joint inflammation with documented negative RF testing
• Chronic inflammatory polyarthritis with negative or unavailable RF lab values
• RA-compatible clinical diagnosis (morning stiffness ≥6 weeks, symmetric involvement) when joint site is not explicitly documented in the record
• Early undifferentiated inflammatory arthritis progressing to a confirmed seronegative RA diagnosis
• Seronegative RA managed with disease-modifying antirheumatic drugs (DMARDs) when site documentation is absent

What Does M06.00 Specifically Exclude?

The M06.0 category excludes conditions that have their own dedicated classification:

• Rheumatoid arthritis with rheumatoid factor → M05.xx (seropositive RA)
• Juvenile idiopathic arthritis (JIA) → M08.xx (never use M06 codes for pediatric patients)
• Adult-onset Still’s disease → M06.1 (separate subcategory under M06)
• Rheumatoid bursitis → M06.2x
• Rheumatoid nodule → M06.3x
• Inflammatory polyarthritis not elsewhere classified → M06.4
• Felty’s syndrome → M05.00–M05.09 (seropositive; requires RF confirmation)
• Psoriatic arthritis → L40.5x (separate chapter; often a differential diagnosis for seronegative presentations)

When Is M06.00 the Right Code to Use?

In practice, coders frequently encounter M06.00 as a “placeholder” code during the initial phase of a rheumatology workup — and that is precisely where its appropriate use and its misuse diverge. This code is justified only when specific criteria are all simultaneously true.

Apply M06.00 when all of the following conditions are met:

1. The treating provider has explicitly documented a diagnosis of rheumatoid arthritis — not merely “arthralgia,” “joint pain,” or “inflammatory arthritis query.”
2. Laboratory results confirm the absence of rheumatoid factor (RF); or the provider has documented the diagnosis as seronegative RA in the absence of available lab results.
3. The anti-CCP (anti-citrullinated protein antibody) test is negative or not reported — because a positive anti-CCP even with negative RF typically shifts the clinical picture toward seropositive disease and may support M05.xx codes.
4. The clinical record does not specify which joint or anatomical site is affected — meaning you cannot justify a more specific M06.0x code (e.g., M06.01 for shoulder, M06.04 for hand).
5. The patient is an adult — seronegative inflammatory arthritis in patients under 16 routes to M08.xx.

How Does M06.00 Differ From M06.09, M06.9, and M05 Codes?

This is the most frequent area of confusion in rheumatology coding. The distinction matters because payers scrutinize unspecified codes and code families differently for medical necessity and prior authorization purposes.

Coding tip from practice: M06.00 and M06.9 are not interchangeable. M06.9 is appropriate when neither the RF status nor the site is known. M06.00 requires affirmative evidence — documented negative RF or provider attestation of seronegative status — before it is assigned.

What Documentation Is Required to Support M06.00?

Inadequate documentation is the primary driver of claim denials and audit findings for all M06-family codes. Because seronegative RA presents no straightforward positive lab value to anchor the diagnosis, the provider’s clinical narrative carries extra evidentiary weight.

What Must the Provider Document in the Clinical Notes?

Auditors and payer reviewers expect to see all of the following documented in the medical record before M06.00 is defensible:

1. Explicit diagnosis statement — The provider must write “rheumatoid arthritis,” “seronegative RA,” or an equivalent clinical term. “Joint pain” or “inflammatory arthritis” alone is insufficient.
2. Seronegative status — A notation confirming negative RF results, or a provider statement such as “RF-negative rheumatoid arthritis” or “seronegative RA.”
3. Duration of symptoms — Morning stiffness lasting ≥6 weeks and symmetric joint involvement are the ACR/EULAR diagnostic hallmarks; documenting these supports medical necessity.
4. Exclusion of alternative diagnoses — Particularly psoriatic arthritis, reactive arthritis (M02.xx), or osteoarthritis (M15–M19), especially in seronegative presentations where differentiation is clinically harder.
5. Treatment plan — Documented initiation of DMARDs (e.g., methotrexate, hydroxychloroquine) reinforces the medical necessity rationale for the RA diagnosis code.
6. Reason site is unspecified — If a coder cannot determine the joint involved, the documentation should reflect early, diffuse, or systemic disease activity rather than simply omitting site data.

Which Lab Results Support This Code?

M06.00 rests on the absence of certain markers rather than their presence. Supporting lab documentation includes:

• Negative RF (rheumatoid factor) assay — documented result, not merely an unstated assumption
• Negative or low-titer anti-CCP antibodies — a high-titer positive anti-CCP shifts the clinical scenario toward seropositive disease
• Elevated ESR (erythrocyte sedimentation rate) or CRP (C-reactive protein) — nonspecific but supportive of active inflammatory disease
• CBC with differential — to rule out hematologic causes; anemia of chronic disease is common in RA
• Imaging reports (X-ray, MRI, or ultrasound) — documenting synovitis, erosions, or joint-space narrowing provides objective evidence of inflammatory arthropathy

What Is the Documentation Standard for Inpatient vs. Outpatient Settings?

How Does M06.00 Affect Medical Billing and Claims?

From a revenue cycle compliance standpoint, M06.00 is what payers classify as an “unspecified site” code — and that designation carries measurable reimbursement risk. While the code is valid and billable, its use for recurring claims (particularly for high-cost biologic therapies) without documentation improvement can trigger medical necessity reviews.

Key billing considerations for M06.00 claims:

• Site-specificity gap: Payers increasingly apply LCD (Local Coverage Determination) policies requiring joint-specific documentation for biologic DMARD authorization — a code like M06.00 may trigger additional information requests
• Medical necessity: Claims for infusion therapy (e.g., IV abatacept, rituximab) paired with M06.00 may face stricter clinical review than M05.xx seropositive codes because the “burden of proof” is higher for seronegative presentations
• Risk adjustment impact: In value-based care models, M06.00 carries lower HCC (Hierarchical Condition Category) weight than more specific or seropositive RA codes — potentially understating patient complexity
• Long-term medication codes: When the patient is on long-term DMARD or immunosuppressant therapy, Z79.6 (Long-term current use of immunosuppressants) or Z79.899 (Long-term use of other medications) should be appended per ICD-10-CM Official Coding Guidelines

What CPT or Procedure Codes Are Commonly Billed With M06.00?

Are There Prior Authorization or Coverage Restrictions for M06.00?

• Biologic DMARDs (e.g., adalimumab, abatacept, tocilizumab) almost universally require prior authorization; payers expect documentation of step therapy failure with conventional DMARDs before approval
• M06.00 paired with a biologic claim without a step-therapy failure note in the record is a high-denial-risk combination
• Medicare LCD policies for rheumatoid arthritis infusion therapy typically require documented diagnosis confirmation, laboratory support, and evidence of inadequate response to first-line therapy
• Some commercial payers require the RF-negative result to be explicitly referenced in the prior authorization letter, not just in the chart — verify payer-specific LCD requirements before submission
• DMARD monitoring labs (CBC, LFTs with methotrexate) should be documented and coded appropriately to demonstrate ongoing clinical management

What Coding Errors Should You Avoid With M06.00?

Auditors commonly flag M06.00 claims for a predictable set of documentation and code-selection failures. The following errors represent the highest-frequency findings in rheumatology coding audits:

1. Using M06.00 when joint site is actually documented — If the chart clearly states “bilateral wrist involvement,” the correct code is M06.03 (wrist), not M06.00. Defaulting to unspecified codes when site data exists is a top OIG audit finding.
2. Confusing M06.00 with M06.9 — Assigning M06.00 when RF status was never tested or documented; M06.9 is the correct choice when serological status is truly unknown.
3. Using M06.00 for pediatric patients — Any patient under 16 with seronegative inflammatory arthritis should be coded from the M08 category (juvenile arthritis), not M06.
4. Failing to add Z79.6 for long-term DMARD use — This secondary code is frequently omitted in rheumatology billing and reduces completeness of the clinical picture for payers.
5. Coding M06.00 from an abnormal lab result alone — A negative RF result is supporting evidence, not a standalone coding trigger. The provider’s diagnostic statement is required.
6. Assigning M06.00 on repeat encounters without re-evaluation — If a provider has documented specific joint involvement at a prior visit, that specificity carries forward; M06.00 may no longer be the most accurate code on subsequent visits.

What Do Auditors Look for When Reviewing Claims With M06.00?

• Evidence in the chart of a provider-authored diagnosis of RA (not inferred by the coder)
• Documented negative RF result or explicit “seronegative” notation
• A clinical rationale for unspecified site — e.g., diffuse polyarthritis, very early disease, or pending imaging
• Consistency between the diagnosis code and the level of E/M service billed (high-complexity M06.00 claims paired with a 99213 draw scrutiny)
• Appropriate use of additional codes for extra-articular manifestations or long-term medication management

How Does M06.00 Relate to Other ICD-10 Codes in the M06 Family?

Understanding M06.00’s position within the broader M06 code family — and its relationship to adjacent categories — is essential for accurate diagnosis code specificity and proper claim submission.

What Is the Correct Code Sequencing When M06.00 Appears With Other Diagnoses?

1. M06.00 as principal/first-listed: Appropriate when seronegative RA is the primary reason for the encounter
2. Extra-articular manifestations: Code any separately managed manifestations (e.g., rheumatoid lung disease — J99, pericarditis — I32) as additional codes after M06.00
3. Long-term medication: Append Z79.6 or Z79.899 after the primary RA code when applicable
4. Comorbid osteoporosis: If the provider documents RA-related osteoporosis, add the appropriate M80.xx or M81.xx code per the “use additional code” instruction
5. Etiology-manifestation sequencing: If M06.00 is the underlying etiology driving another condition (e.g., secondary Sjögren’s-like symptoms), follow the tabular instruction; RA codes generally sequence first

Real-World Coding Scenario — How M06.00 Is Applied in Practice

Patient encounter: A 52-year-old female presents to her rheumatologist for an established office visit. She was diagnosed with seronegative RA six months ago. Today’s note reads: “Patient continues on methotrexate 15 mg weekly. RF and anti-CCP were negative at baseline. She reports improved morning stiffness. Joint examination today limited to hand assessment — bilateral MCP and PIP joints tender but less swollen than prior visit. Will continue current regimen.”

The coder must determine: is M06.00 still appropriate, or has documentation evolved to support a more specific code?

Correct Code Application

• Primary diagnosis: M06.04 — Rheumatoid arthritis without rheumatoid factor, hand (bilateral hand involvement now documented in this encounter)
• Secondary code: Z79.6 — Long-term (current) use of immunosuppressants (methotrexate)
• Procedure code: 99213 or 99214 — Established patient E/M (level determined by MDM or time)

Rationale: The provider explicitly documents bilateral hand (MCP, PIP joint) involvement in today’s exam. The site is now specified — M06.00 is no longer the most accurate code; M06.04 captures the documented clinical picture.

Common Mistake in This Scenario

• Incorrect code: M06.00 — A coder defaults to the familiar unspecified code from the prior visit without reading today’s examination findings
• Why it fails: M06.00 is appropriate only when site is not documented; the joint-specific documentation from this encounter obligates a more specific M06.0x code
• Audit consequence: Pattern use of M06.00 across repeated visits where site documentation exists is a red flag in coding audit preparation reviews and can result in repayment demands

Frequently Asked Questions About ICD-10 Code M06.00

Is ICD-10 Code M06.00 Still Valid for Use in 2026?

ICD-10 code M06.00 remains a valid, billable diagnosis code for fiscal year 2026 with no changes to its description or validity status as of October 1, 2025. Coders should verify annually against the ICD-10-CM Official Coding Guidelines release published by CMS to confirm no modifications have been applied to the M06 code family.

What Is the Difference Between M06.00 and M06.09?

M06.00 is used when seronegative rheumatoid arthritis is confirmed but no specific anatomical site is documented in the clinical record. M06.09 is the appropriate code when the provider’s documentation confirms that multiple joints are affected — the two codes are siblings within the M06.0 family and are not interchangeable based on payer preference alone.

Can I Use M06.00 and M05 Codes Together on the Same Claim?

M05 and M06.0 codes are mutually exclusive as primary RA diagnosis codes — a patient cannot be simultaneously seropositive and seronegative. The one exception is coding a separate M06-family manifestation code (such as M06.3x for rheumatoid nodule) alongside an M05.xx primary code, which is explicitly supported in the ICD-10-CM tabular instructions.

What Happens if the RF Lab Result Is Never Documented — Can I Still Use M06.00?

No. If the rheumatoid factor result is neither documented nor referenced by the provider, M06.00 is not appropriate. The correct code in that scenario is M06.9 (rheumatoid arthritis, unspecified), which covers encounters where neither the serological status nor the site is established in the medical record.

Does M06.00 Qualify for Biologic DMARD Authorization Under Medicare?

M06.00 can appear on prior authorization requests for biologic DMARDs, but it carries higher scrutiny than seropositive (M05.xx) codes because seronegative RA requires more robust clinical documentation to establish medical necessity. Billing teams should ensure the authorization package includes the negative RF result, ACR functional class documentation, and evidence of inadequate response to conventional DMARDs per applicable LCD policy — not just the diagnosis code.

What Additional Codes Should Always Be Reported With M06.00?

When clinically applicable, the following secondary codes are frequently required or strongly recommended alongside M06.00:

• Z79.6 — Long-term (current) use of immunosuppressants (for patients on methotrexate, azathioprine, or biologic agents)
• Z79.899 — Long-term use of other medications (for leflunomide, hydroxychloroquine)
• M06.3x — Rheumatoid nodule (if documented as a manifestation)
• Site-specific M06.0x codes should replace M06.00 — not supplement it — once site documentation becomes available

Key Takeaways

For any coder or biller working with rheumatology claims, M06.00 is a high-utility but frequently misapplied code. Keep these points front of mind:

• M06.00 is seronegative + site unspecified — both conditions must be true simultaneously; it is not a catch-all RA code
• Negative RF documentation is required — without it, M06.9 is the correct fallback, not M06.00
• Site-specific codes (M06.01–M06.09) always take priority when joint documentation exists — do not default to M06.00 out of habit
• M06.00 ≠ M06.9 ≠ M05.xx — each code serves a distinct clinical and documentation scenario; conflating them is a top audit finding
• Add Z79.6 for long-term DMARD therapy — this secondary code is frequently omitted and reduces claim completeness
• Prior authorization for biologics with M06.00 requires robust clinical narrative beyond the code itself — step therapy documentation is critical
• Re-evaluate the code at every encounter — seronegative RA documentation evolves; M06.00 should not carry forward indefinitely if site specificity has been established

For authoritative coding guidance, consult the CMS ICD-10-CM Official Coding Guidelines, the AHA Coding Clinic for RA-specific Coding Clinic advice, and CDC ICD-10 resources for annual code set updates.